Trial Profile
A phase III study of ABM-125 in poorly controlled asthmatics susceptible to exacerbations following naturally acquired rhinovirus infection
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 23 May 2017
Price :
$35
*
At a glance
- Drugs LNR 125.38 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 23 May 2017 New trial record